Testosterone supplements and new AUA guidelines on management of testosterone deficiency

The increasingly widespread use of testosterone supplements has been of concern for many years. In particular, for men with a history of prostate cancer diagnosis, the appropriate use of testosterone supplementation has been a matter of special focus. … READ MORE …

Two leading women talk about the future of treatment of advanced prostate cancer

Nearly 30 years ago, when your sitemaster first attended a prostate cancer meeting (in 1989) related to the upcoming approval of a new drug called flutamide, he doesn’t remember there being a single clinician at the meeting who was female — out of the 150 or so urologists and medical oncologists who had been invited. … READ MORE …

ASCO issues new guidelines on treatment of metastatic prostate cancer

New guidelines on the management of metastatic, hormone-sensitive prostate cancer have just been released by the American Society for Clinical Oncology (ASCO), based primarily on data from the CHAARTED, STAMPEDE, and LATITUDE trial data. … READ MORE …

Should perineural invasion influence active surveillance and radiation treatment options?

Perineural invasion (PNI) is a risk factor detected on a biopsy in 15 to 38 percent of men with a prostate cancer diagnosis. … READ MORE …

Major US insurer to cover use of HIFU for treatment of radiorecurrent prostate cancer

According to a media release issued on March 18 by EDAP TMS, the US healthcare insurance firm CIGNA has agreed to cover the use of high-intensity focal ultrasound (HIFU) as a second-line, salvage therapy for men with radiorecurrent prostate cancer. … READ MORE …

A PSMA-based PET scan can change SRT decisions

The new PSMA-based PET scans provide a way to locate exactly where the cancer has spread to after an unsuccessful prostatectomy. … READ MORE …

What to do first for men with mCRPC

The currently “great unanswered” question in the management of advanced prostate cancer is the order of agents to be used in the treatment of men who are receiving first-line therapy for metastatic prostate cancer after it becomes castration-resistant. … READ MORE …